Literature DB >> 18347990

Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration.

Debra Kerr1, Paul Dietze, Anne-Maree Kelly, Damien Jolley.   

Abstract

Naloxone distribution to injecting drug users (IDUs) for peer administration is a suggested strategy to prevent fatal heroin overdose. The aim of this study was to explore attitudes of IDUs to administration of naloxone to others after heroin overdose, and preferences for method of administration. A sample of 99 IDUs (median age 35 years, 72% male) recruited from needle and syringe programs in Melbourne were administered a questionnaire. Data collected included demographics, attitudes to naloxone distribution, and preferences for method of administration. The primary study outcomes were attitudes of IDUs to use of naloxone for peer administration (categorized on a five-point scale ranging from "very good idea" to "very bad idea") and preferred mode of administration (intravenous, intramuscular, and intranasal). The majority of the sample reported positive attitudes toward naloxone distribution (good to very good idea: 89%) and 92% said they were willing to participate in a related training program. Some participants raised concerns about peer administration including the competence of IDUs to administer naloxone in an emergency, victim response on wakening and legal implications. Most (74%) preferred intranasal administration in comparison to other administration methods (21%). There was no association with age, sex, or heroin practice. There appears to be strong support among Australian IDU for naloxone distribution to peers. Intranasal spray is the preferred route of administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347990      PMCID: PMC2329742          DOI: 10.1007/s11524-008-9273-z

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  24 in total

1.  Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes.

Authors:  K Dettmer; B Saunders; J Strang
Journal:  BMJ       Date:  2001-04-14

2.  Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco.

Authors:  Peter J Davidson; Kristen C Ochoa; Judith A Hahn; Jennifer L Evans; Andrew R Moss
Journal:  Addiction       Date:  2002-12       Impact factor: 6.526

3.  Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose.

Authors:  Anne-Maree Kelly; Debra Kerr; Paul Dietze; Ian Patrick; Tony Walker; Zeff Koutsogiannis
Journal:  Med J Aust       Date:  2005-01-03       Impact factor: 7.738

4.  Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose?

Authors:  S R Lenton; K M Hargreaves
Journal:  Med J Aust       Date:  2000-09       Impact factor: 7.738

5.  Overdose among heroin users in Sydney, Australia: II. responses to overdose.

Authors:  S Darke; J Ross; W Hall
Journal:  Addiction       Date:  1996-03       Impact factor: 6.526

6.  The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the prehospital setting.

Authors:  Kate Cantwell; Paul Dietze; Louisa Flander
Journal:  Resuscitation       Date:  2005-06       Impact factor: 5.262

7.  Overdoses among friends: drug users are willing to administer naloxone to others.

Authors:  Tara Lagu; Bradley J Anderson; Michael Stein
Journal:  J Subst Abuse Treat       Date:  2006-03

8.  Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area.

Authors:  Karen H Seal; Moher Downing; Alex H Kral; Shannon Singleton-Banks; Jon-Paul Hammond; Jennifer Lorvick; Dan Ciccarone; Brian R Edlin
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

9.  Opiate users' knowledge about overdose prevention and naloxone in New York City: a focus group study.

Authors:  Nancy Worthington; Tinka Markham Piper; Sandro Galea; David Rosenthal
Journal:  Harm Reduct J       Date:  2006-07-05

10.  Homeless drug users' awareness and risk perception of peer "take home naloxone" use--a qualitative study.

Authors:  Nat Wright; Nicola Oldham; Katharine Francis; Lesley Jones
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-10-02
View more
  5 in total

1.  Attitudes Toward Naloxone Prescribing in Clinical Settings: A Qualitative Study of Patients Prescribed High Dose Opioids for Chronic Non-Cancer Pain.

Authors:  Shane R Mueller; Stephen Koester; Jason M Glanz; Edward M Gardner; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2016-10-31       Impact factor: 5.128

Review 2.  A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice.

Authors:  Shane R Mueller; Alexander Y Walley; Susan L Calcaterra; Jason M Glanz; Ingrid A Binswanger
Journal:  Subst Abus       Date:  2015-03-16       Impact factor: 3.716

3.  UNDERSTANDING PREFERENCES FOR TYPE OF TAKE-HOME NALOXONE DEVICE: INTERNATIONAL QUALITATIVE ANALYSIS OF THE VIEWS OF PEOPLE WHO USE OPIOIDS.

Authors:  Joanne Neale; Adrian Farrugia; Aimee N Campbell; Paul Dietze; Robyn Dwyer; Renae Fomiatti; Jermaine D Jones; Sandra D Comer; Suzanne Fraser; John Strang
Journal:  Drugs (Abingdon Engl)       Date:  2021-02-22

Review 4.  Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature.

Authors:  Silvia S Martins; Laura Sampson; Magdalena Cerdá; Sandro Galea
Journal:  Am J Public Health       Date:  2015-11       Impact factor: 9.308

5.  Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis.

Authors:  Joanne Neale; Nicola J Kalk; Stephen Parkin; Caral Brown; Laura Brandt; Aimee N C Campbell; Felipe Castillo; Jermaine D Jones; John Strang; Sandra D Comer
Journal:  J Subst Abuse Treat       Date:  2020-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.